Biopharma r3

Aldeyra's Reproxalap has Experts Mixed on Seasonal Allergic Conjunctivitis Focus in Phase III

Eisai's Lenvima for First-line HCC Is Approvable but Noninferiority Data to SOC May Slow Uptake

Immunomedics’ Sacituzumab Has Insufficient Dataset to Pursue Accelerated Approval

Shooting for the Universe

Biosimilar Uptake Still Plagued by Interchangeability Hurdles

Alnylam vs Dicerna Trade Secret Litigation May Be Influenced by Emotive Arguments

BeiGene’s Phase III BGB-3111 in WMHas Unclear Efficacy Advantage Over Imbruvica

Corbus’ Phase II Anabasum in Dermatomyositis Garners Mixed Expert Expectations

Strategic Shift of Dong-A ST Co. Ltd. in Drug Discovery

Medical Device: Growing Cybersecurity Threat and Need for More Regulation

Eisai’s Lenvima Should See FDA Approval in Hepatocellular Carcinoma (HCC)

Western CAR-Ts face Chinese Development Hurdles Due to Regulatory Uncertainty

Legislation to Force Payer Coverage of AbuseDeterrent Opioids Faces Resistance

Roche’s GALLIUM Results Draw Skepticism about Changing Practice in First-Line Follicular Lymphoma

Humira Biosimilar Unlikely to Reach the Market Before 2020

BioPharmaceutical

Report

Aldeyra's Reproxalap has Experts Mixed on Seasonal Allergic Conjunctivitis Focus in Phase III

Eisai's Lenvima for First-line HCC Is Approvable but Noninferiority Data to SOC May Slow Uptake

Immunomedics’ Sacituzumab Has Insufficient Dataset to Pursue Accelerated Approval

Shooting for the Universe

Biosimilar Uptake Still Plagued by Interchangeability Hurdles

Alnylam vs Dicerna Trade Secret Litigation May Be Influenced by Emotive Arguments

BeiGene’s Phase III BGB-3111 in WMHas Unclear Efficacy Advantage Over Imbruvica

Corbus’ Phase II Anabasum in Dermatomyositis Garners Mixed Expert Expectations

Strategic Shift of Dong-A ST Co. Ltd. in Drug Discovery

Medical Device: Growing Cybersecurity Threat and Need for More Regulation

Eisai’s Lenvima Should See FDA Approval in Hepatocellular Carcinoma (HCC)

Western CAR-Ts face Chinese Development Hurdles Due to Regulatory Uncertainty

Legislation to Force Payer Coverage of AbuseDeterrent Opioids Faces Resistance

Roche’s GALLIUM Results Draw Skepticism about Changing Practice in First-Line Follicular Lymphoma

Humira Biosimilar Unlikely to Reach the Market Before 2020

Subscribe to Our Journal